JP7527309B2 - Ｆｇｆｒ阻害剤およびそれらの使用 - Google Patents

Ｆｇｆｒ阻害剤およびそれらの使用 Download PDF

Info

Publication number
JP7527309B2
JP7527309B2 JP2021566480A JP2021566480A JP7527309B2 JP 7527309 B2 JP7527309 B2 JP 7527309B2 JP 2021566480 A JP2021566480 A JP 2021566480A JP 2021566480 A JP2021566480 A JP 2021566480A JP 7527309 B2 JP7527309 B2 JP 7527309B2
Authority
JP
Japan
Prior art keywords
nitrogen
independently selected
oxygen
sulfur
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533570A5 (https=
JP2022533570A (ja
Inventor
バカリー－バリー トゥーレ，
ハイケ シェーンハー，
アレクサンダー エム． テイラー，
ファブリジオ ジョーダネット，
ディミトリ ティー． ムスタカス，
トーマス エイチ． マクリーン，
ブランディ エム． ハドソン，
メアリー エム． メイダー，
ペリン アヤズ，
ダイナ エー． シャロン，
ラヴィ クルクラスリヤ，
アレッサンドロ ボエツィオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DEShaw Research LLC
Original Assignee
DEShaw Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DEShaw Research LLC filed Critical DEShaw Research LLC
Publication of JP2022533570A publication Critical patent/JP2022533570A/ja
Publication of JP2022533570A5 publication Critical patent/JP2022533570A5/ja
Priority to JP2024117746A priority Critical patent/JP2024156729A/ja
Application granted granted Critical
Publication of JP7527309B2 publication Critical patent/JP7527309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021566480A 2019-05-13 2020-05-12 Ｆｇｆｒ阻害剤およびそれらの使用 Active JP7527309B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024117746A JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846991P 2019-05-13 2019-05-13
US62/846,991 2019-05-13
US202062993957P 2020-03-24 2020-03-24
US62/993,957 2020-03-24
US202063011469P 2020-04-17 2020-04-17
US63/011,469 2020-04-17
PCT/US2020/032474 WO2020231990A1 (en) 2019-05-13 2020-05-12 Fgfr inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024117746A Division JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2022533570A JP2022533570A (ja) 2022-07-25
JP2022533570A5 JP2022533570A5 (https=) 2023-05-19
JP7527309B2 true JP7527309B2 (ja) 2024-08-02

Family

ID=73289291

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021566480A Active JP7527309B2 (ja) 2019-05-13 2020-05-12 Ｆｇｆｒ阻害剤およびそれらの使用
JP2024117746A Pending JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024117746A Pending JP2024156729A (ja) 2019-05-13 2024-07-23 Ｆｇｆｒ阻害剤およびそれらの使用

Country Status (17)

Country Link
US (2) US12522605B2 (https=)
EP (2) EP3968999B1 (https=)
JP (2) JP7527309B2 (https=)
KR (2) KR20260030158A (https=)
CN (2) CN114126620B (https=)
AU (2) AU2020274083B9 (https=)
BR (1) BR112021022457A2 (https=)
CA (1) CA3137458A1 (https=)
CL (1) CL2021002882A1 (https=)
ES (1) ES2974985T3 (https=)
IL (2) IL287940B2 (https=)
MX (1) MX2021013146A (https=)
PE (1) PE20220573A1 (https=)
PH (1) PH12021552862A1 (https=)
SG (1) SG11202111327XA (https=)
TW (1) TWI855070B (https=)
WO (1) WO2020231990A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
JP2021017595A (ja) * 2019-07-18 2021-02-15 花王株式会社 アニオン変性セルロース
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
EP4143196A4 (en) 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
CN115160319B (zh) * 2021-04-01 2023-12-26 西安新通药物研究股份有限公司 含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
WO2022206939A1 (zh) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 作为fgfr抑制剂的杂环化合物及其应用
CN117677621A (zh) * 2021-08-04 2024-03-08 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
KR20240075952A (ko) * 2021-09-23 2024-05-30 3에이치 파머슈티컬즈 컴퍼니 리미티드 Fgfr 억제제 및 이의 사용 방법
WO2023104035A1 (zh) * 2021-12-06 2023-06-15 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物，其制法与医药上的用途
JP2025505230A (ja) * 2022-02-08 2025-02-21 上海奕拓醫藥科技有限責任公司 二環式ヘテロアリール化合物およびその使用
EP4499616A4 (en) * 2022-03-31 2025-10-29 Acerand Therapeutics Hong Kong Ltd SPIROBICYLICIOUS COMPOUNDS
WO2023202625A1 (zh) * 2022-04-20 2023-10-26 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法
WO2023220131A2 (en) * 2022-05-10 2023-11-16 Relay Therapeutics, Inc. PI3Kα INHIBITORS AND METHODS OF USE THEREOF
CN117186103A (zh) * 2022-06-01 2023-12-08 安徽诺全药业有限公司 氘代杂环化合物及其制备方法和应用
CN119421872A (zh) * 2022-06-29 2025-02-11 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202412758A (zh) * 2022-06-29 2024-04-01 香港商英矽智能科技知識產權有限公司 Fgfr2與fgfr3抑制劑及其用途
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
AU2023338193A1 (en) * 2022-09-07 2025-03-20 Eli Lilly And Company Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives as fgfr3 inhibitors for the treatment of cancer
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
CN115594682B (zh) * 2022-10-26 2024-03-15 苏州浦合医药科技有限公司 Fgfr2抑制剂
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
CN120752227A (zh) * 2023-02-24 2025-10-03 希格生科（深圳）有限公司 α，β-不饱和酰胺类化合物及其应用
CN120712269A (zh) * 2023-03-20 2025-09-26 英矽智能科技知识产权有限公司 Fgfr2和fgfr3的抑制剂及其用途
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
CN121263414A (zh) * 2023-05-26 2026-01-02 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用
CN119894900A (zh) * 2023-06-05 2025-04-25 康百达（四川）生物医药科技有限公司 一种吡咯并嘧啶衍生物及其在医药上的应用
CN117343068B (zh) * 2023-09-28 2026-04-28 上海相辉医药科技有限公司 一种FGFR2抑制剂Lirafugratinib(RLY-4008)的制备方法
WO2025067484A1 (en) * 2023-09-28 2025-04-03 Acerand Therapeutics (Hong Kong) Limited Crystal forms and salts of spirobicyclic compound
CN121693505A (zh) * 2023-11-17 2026-03-17 上海齐鲁制药研究中心有限公司 含氮杂芳基衍生物、其制备方法及其在医药上的应用
WO2025140636A1 (zh) * 2023-12-29 2025-07-03 广州科恩泰生物医药科技有限公司 一种亚砜亚胺类化合物的酸式盐的晶型及其制备方法和用途
WO2025149021A1 (zh) * 2024-01-10 2025-07-17 海思科医药集团股份有限公司 一种吡啶并吡咯衍生物及其在医药上的应用
WO2025237312A1 (zh) * 2024-05-15 2025-11-20 深圳福沃药业有限公司 一类含苯并异噁唑结构的高选择性fgfr2抑制剂及其制备方法和应用
CN121270563A (zh) * 2024-07-01 2026-01-06 北京鞍石生物科技股份有限公司 稠环化合物及其制备方法和应用
CN120136834B (zh) * 2025-02-13 2026-02-03 浙江工业大学 一种手性吡喃环化合物及其合成方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001839A (en) 1997-03-19 1999-12-14 Basf Aktiengesellschaft Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
US6140332A (en) 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
WO2005121147A1 (en) 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006004703A2 (en) 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB119249A (en) 1917-06-09 1918-10-03 Du Pont Process of Producing Alcohols.
US2319070A (en) 1938-03-31 1943-05-11 Eastman Kodak Co Manufacture of unsaturated aliphatic acids and anhydrides
KR100296810B1 (ko) 1993-03-12 2001-10-24 로렌스 티. 마이젠헬더 결정성세프티오퍼유리산
WO1998007726A1 (en) * 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CA2285455A1 (en) 1997-04-09 1998-10-15 Sebastian Mario Marcuccio Process for covalently coupling organic compounds utilizing diboron derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
RU2358975C2 (ru) 2003-08-26 2009-06-20 Тейдзин Фарма Лимитед Пирролопиримидиноновые производные
US7892354B2 (en) 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
MXPA06015223A (es) * 2004-06-29 2007-11-09 Amgen Inc Furanopirimidinas.
DE102005061170A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102286048A (zh) * 2011-06-24 2011-12-21 吉林大学 4-氨基-6-(3-(3-溴苯基)苯基)-5-氰基-7-(β-L-呋喃木糖)吡咯并[2, 3-d]嘧啶、同类衍生物及用于制备抗肿瘤药物
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
EP2788000B1 (en) 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
MY171055A (en) 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3015484C (en) * 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2020231990A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
WO2021052499A1 (zh) 2019-09-20 2021-03-25 上海济煜医药科技有限公司 稠合吡啶酮类化合物及其制备方法和应用
CN114585610A (zh) 2019-10-28 2022-06-03 日本曹达株式会社 2,6-二氧代-3,6-二氢嘧啶化合物以及农业园艺用杀菌剂、杀线虫剂、及医疗用·动物用抗真菌剂
TW202132316A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
US20230219904A1 (en) 2020-04-17 2023-07-13 Syngenta Crop Protection Ag Herbicidal compounds
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140332A (en) 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US6001839A (en) 1997-03-19 1999-12-14 Basf Aktiengesellschaft Substituted 4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors
WO2005121147A1 (en) 2004-06-03 2005-12-22 Bayer Pharmaceuticals Corporation Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006004703A2 (en) 2004-06-29 2006-01-12 Amgen Inc. PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY

Also Published As

Publication number Publication date
US20230192709A1 (en) 2023-06-22
EP4306529A3 (en) 2024-04-10
TWI855070B (zh) 2024-09-11
TW202108141A (zh) 2021-03-01
IL287940B1 (en) 2025-11-01
ES2974985T3 (es) 2024-07-02
EP3968999A1 (en) 2022-03-23
IL287940A (en) 2022-01-01
EP4306529A2 (en) 2024-01-17
EP3968999B1 (en) 2023-12-27
KR20260030158A (ko) 2026-03-05
CN119874707A (zh) 2025-04-25
AU2020274083B2 (en) 2025-04-24
AU2025202494A1 (en) 2025-05-01
EP4306529C0 (en) 2026-01-21
PH12021552862A1 (en) 2022-12-19
SG11202111327XA (en) 2021-11-29
CN114126620A (zh) 2022-03-01
AU2020274083A1 (en) 2021-11-18
US11780845B2 (en) 2023-10-10
PE20220573A1 (es) 2022-04-20
JP2024156729A (ja) 2024-11-06
US20230104574A1 (en) 2023-04-06
EP4306529B1 (en) 2026-01-21
JP2022533570A (ja) 2022-07-25
IL287940B2 (en) 2026-03-01
US12522605B2 (en) 2026-01-13
CA3137458A1 (en) 2020-11-19
IL323675A (en) 2025-11-01
TW202525809A (zh) 2025-07-01
WO2020231990A1 (en) 2020-11-19
BR112021022457A2 (pt) 2022-03-22
AU2020274083B9 (en) 2025-05-01
MX2021013146A (es) 2022-01-24
CN114126620B (zh) 2024-12-31
CL2021002882A1 (es) 2022-10-07
EP3968999A4 (en) 2022-08-03
KR102923990B1 (ko) 2026-02-09
KR20220007889A (ko) 2022-01-19

Similar Documents

Publication Publication Date Title
JP7527309B2 (ja) Ｆｇｆｒ阻害剤およびそれらの使用
JP2024507131A (ja) Ｃｄｋ阻害薬及びその使用方法
AU2014362231B2 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2018372211A1 (en) Heterocyclic compounds as PRMT5 inhibitors
AU2019234670A1 (en) Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EP2124951A1 (en) 5-cyan0-4- (pyrrolo ý2, 3b¨pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AU2014348191A1 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
AU2016203414A1 (en) Compounds useful as inhibitors of ATR kinase
AU2014234909B2 (en) Acyclic cyanoethylpyrazolo pyridones as Janus kinase inhibitors
WO2023154426A1 (en) Cdk inhibitors and methods of use thereof
CA2901766A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
TWI921912B (zh) Fgfr抑制劑及其使用方法
HK40107335A (en) Fgfr inhibitors and methods of use thereof
EP4522606A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
HK40070481B (en) Fgfr inhibitors and methods of use thereof
HK40070481A (en) Fgfr inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240723

R150 Certificate of patent or registration of utility model

Ref document number: 7527309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150